ライフサイエンスコーパス: dose-limiting toxicity

1 um tolerated dose of CPI-613 (as assessed by dose-limiting toxicities).

2 thrombocytopenia, which has proven to be the dose-limiting toxicity.

3 ng for the mechanistic basis of efficacy and dose-limiting toxicity.

4 tion was well tolerated, without evidence of dose-limiting toxicity.

5 Phase I revealed no dose-limiting toxicity.

6 No patient had a dose-limiting toxicity.

7 Rash was the most frequent and dose-limiting toxicity.

8 hrombocytopenia that required transfusion, a dose-limiting toxicity.

9 end points were progressive KS and recurrent dose-limiting toxicity.

10 higher dose of 1000 mg/m(2), and both had a dose-limiting toxicity.

11 atients received pomalidomide 2 mg/d with no dose-limiting toxicity.

12 with grade 2 adverse events (AEs) defined as dose-limiting toxicity.

13 le cerebellar toxicity, thereby defining the dose-limiting toxicity.

14 aximum of 30 mg per week, until remission or dose-limiting toxicity.

15 the timing of therapeutic interventions, and dose-limiting toxicity.

16 T-cell infusions were well tolerated with no dose-limiting toxicity.

17 ntered the phase 1 study; none experienced a dose-limiting toxicity.

18 Thrombocytopenia and leukopenia were the dose-limiting toxicities.

19 ted to a maximum of 0.24 mg/kg/d without any dose-limiting toxicities.

20 Vaccinations at all DL were safe with no dose-limiting toxicities.

21 preparative regimens is not feasible due to dose-limiting toxicities.

22 isting active-site antifolate drugs can have dose-limiting toxicities.

23 was maintained throughout treatment with no dose-limiting toxicities.

24 The primary end point was incidence of dose-limiting toxicities.

25 microg was tested without the appearance of dose-limiting toxicities.

26 Three patients experienced dose-limiting toxicities: 1 at 4.0 mg and 2 at 5.5 mg; t

27 ive patients were treated; seven experienced dose-limiting toxicities (all hematologic).

28 atients in cohort 1 and four in cohort 3 had dose-limiting toxicities; all other patients were treate

29 Patients in the dose-limiting toxicity analysis set were assessed for th

30 18 patients were analysed in the dose-limiting toxicity analysis set: three at dose level

31 py, but later elicit minimal response due to dose-limiting toxicities and acquired resistance.

32 glands as well as to the kidney, leading to dose-limiting toxicities and adverse events affecting qu

33 remarkably improved MM patient outcome, but dose-limiting toxicities and development of resistance l

34 No dose-limiting toxicities and no individual dose reductio

35 ly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistan

36 eir cytotoxin delivery to tumor with reduced dose-limiting toxicities and thus have the potential for

37 Radiotherapy causes dose-limiting toxicity and long-term complications in ra

38 Primary end points included dose-limiting toxicity and maximum tolerated dose (MTD).

39 y of TPCS2a; other co-primary endpoints were dose-limiting toxicity and maximum tolerated dose.

40 e available small molecule drugs suffer from dose-limiting toxicity and undesirable side effects.

41 nia due to BCL-x(l) inhibition was the major dose-limiting toxicity and was dose-related.

42 med to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-35

43 et were assessed for the primary endpoint of dose-limiting toxicity, and all patients enrolled in the

44 , difficulty in purification to homogeneity, dose-limiting toxicity, and chemical instability.

45 to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of re

46 determine the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of oral iri

47 No patient experienced dose-limiting toxicity, and the maximum tolerated dose w

48 st one dose of rilotumumab and completed the dose-limiting toxicity assessment window (first cycle of

49 Due to dose-limiting toxicities associated with inhibition of w

50 The two dose-limiting toxicities at 1,000 mg/m2/d involved grade

51 One patient experienced dose-limiting toxicity at 4 mg; the MTD was determined a

52 t least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully

53 i-cancer small molecule drugs as well as the dose-limiting toxicity caused by the nonselective action

54 Thus, dose-limiting toxicities commonly associated with these

55 Dose limiting toxicity comprising neutropenic sepsis (on

56 Dose-limiting toxicities consisted primarily of transien

57 However, the dose limiting toxicity delays diarrhea that is thought t

58 Neurologic dose-limiting toxicity developed in 3 patients; however,

59 termine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered

60 determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of

61 tudy was undertaken to determine the safety, dose-limiting toxicities (DLT), maximum-tolerated dose (

62 Primary end points included determination of dose-limiting toxicity (DLT) and a phase II dose; second

63 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose

64 Dose-limiting toxicity (DLT) consisted of elevation of b

65 Dose-limiting toxicity (DLT) consisted of worsening neur

66 At 110 mg/m(2)/d, two of four patients had dose-limiting toxicity (DLT) consisting of rash and hype

67 Study characteristics, design parameters, dose-limiting toxicity (DLT) definition, DLT rate, patie

68 Tumor lysis syndrome was the dose-limiting toxicity (DLT) for CLL, the maximum-tolera

69 ses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irrespective of

70 The primary endpoint was dose-limiting toxicity (DLT) in the first treatment cycl

71 % escalations in three patient cohorts until dose-limiting toxicity (DLT) occurred.

72 termine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of bevacizumab, when added

73 dentify the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients w

74 om 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversibl

75 rases that met protocol-defined criteria for dose-limiting toxicity (DLT) or temporarily holding ther

76 reated every 2 weeks x 4 doses with a 4-week dose-limiting toxicity (DLT) period.

77 to determine the dose level associated with dose-limiting toxicity (DLT) through cycle 2 in < or = 2

78 Treatment-related dose-limiting toxicity (DLT) was defined as any grade 3

79 Dose-limiting toxicity (DLT) was defined as any nonhemat

80 Dose-limiting toxicity (DLT) was defined as grade 3 or w

81 No dose-limiting toxicity (DLT) was encountered on dose lev

82 Dose-limiting toxicity (DLT) was failure to reconstitute

83 Dose-limiting toxicity (DLT) was observed at the third a

84 48 mg/m(2)/d and continued until consistent dose-limiting toxicity (DLT) was observed.

85 olled and evaluable, the number experiencing dose-limiting toxicity (DLT), and the number still at ri

86 The primary endpoint was dose-limiting toxicity (DLT), assessed during the first

87 a was the most common drug-related (93%) and dose-limiting toxicity (DLT), constituting four of 10 DL

88 Dose-limiting toxicity (DLT), maximum-tolerated dose (MT

89 o evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), and

90 establish the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics,

91 toxicity, and 34 patients were evaluable for dose-limiting toxicity (DLT).

92 Primary outcome was safety and dose-limiting toxicity (DLT).

93 increased by 20 mg/m(2)/d in the absence of dose-limiting toxicity (DLT).

94 The study end point was dose-limiting toxicity (DLT).

95 mum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of

96 he maximum-tolerated dose (MTD) and describe dose-limiting toxicities (DLTs) and the incidence and se

97 Dose-limiting toxicities (DLTs) in the MONO study were f

98 Dose-limiting toxicities (DLTs) included perforated ulce

99 d dose was determined to be 60 mg/m(2), with dose-limiting toxicities (DLTs) of fatigue, nausea, vomi

100 Dose-limiting toxicities (DLTs) were assessed during cyc

101 Dose-limiting toxicities (DLTs) were assessed during the

102 Using a 3 + 3 design, dose-limiting toxicities (DLTs) were assessed weekly dur

103 Dose-limiting toxicities (DLTs) were defined as treatmen

104 Dose-limiting toxicities (DLTs) were evaluated during th

105 Dose-limiting toxicities (DLTs) were grade 3 hypersensit

106 No dose-limiting toxicities (DLTs) were observed at the 50,

107 No dose-limiting toxicities (DLTs) were observed in patient

108 determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic and

109 determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic pro

110 ermine maximum-tolerated dose (MTD), safety, dose-limiting toxicities (DLTs), and pharmacokinetics (P

111 ur knowledge) phase I study to determine the dose-limiting toxicities (DLTs), characterize the pharma

112 te plus romidepsin designed to determine the dose-limiting toxicities (DLTs), maximum tolerated dose,

113 mum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and b

114 imum-tolerated dose (MTD), toxicity profile, dose-limiting toxicities (DLTs), pharmacokinetics, and p

115 ade 3 hand-foot skin reaction and/or rash as dose-limiting toxicities (DLTs).

116 f 100 and 125 mg/m(2) were tolerated without dose-limiting toxicities (DLTs).

117 Initially, six patients developed dose-limiting toxicities (DLTs): grade (G) 2 nausea at 1

118 Two patients experienced dose-limiting toxicity due to ch14.18 and IL-2.

119 The primary endpoint was dose-limiting toxicities during cycle 1 according to inv

120 ion algorithm and depending on the number of dose-limiting toxicities during the first 3-week assessm

121 bjectives were to determine the incidence of dose-limiting toxicities during the first cycle of CMP t

122 The primary safety outcome was dose-limiting toxicity effects.

123 One dose-limiting toxicity event (grade 3 abdominal pain) oc

124 There were no dose-limiting toxicity events in either group.

125 Three dose-limiting toxicity events of grade 3 mouth sores wer

126 We conclude that thrombocytopenia is the dose limiting toxicity for boronated porphyrins in mamma

127 ry endpoints were maximum tolerated dose and dose-limiting toxicity for phase 1, and the proportion o

128 Hypertension is a dose-limiting toxicity for VEGF inhibitors.

129 T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibi

130 xamined because of recurrent grade 2 and non-dose-limiting toxicity grade 3 and 4 adverse events (AEs

131 Two dose-limiting toxicities (grade 2 pulmonary embolism and

132 in the 450 mg dose-escalation cohort had two dose-limiting toxicities (grade 3 diarrhoea and grade 3

133 Two dose-limiting toxicities (grade 3 rash; grade 4 thromboc

134 There were four dose-limiting toxicities (grade 4 neutropenia) at 5 mg p

135 Dose-limiting toxicity (grade 3 anorexia) occurred in on

136 Dose-limiting toxicity (grade 3/4 diarrhea) occurred at

137 Only one patient experienced a dose-limiting toxicity-grade 3 transient asymptomatic hy

138 eight patients, four experienced unexpected dose-limiting toxicities: grade 4 sepsis syndrome, grade

139 Two patients experienced dose-limiting toxicity: grade 3 conjunctivitis and trans

140 Eight of nine patients with dose-limiting toxicity had grade 4 thrombocytopenia.

141 ed clinical activity in cancer patients, but dose-limiting toxicities have hindered its incorporation

142 tient number 2; anaemia and lymphopenia were dose-limiting toxicities); hyperglycaemia (in patient nu

143 One dose-limiting toxicity (ie, grade 3 thrombocytopenia) oc

144 which expanded to six patients because of a dose-limiting toxicity (ie, junctional cardiac rhythm).

145 al application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 10

146 ase 1b primary endpoint was the incidence of dose-limiting toxicities in all phase 1b patients who re

147 nd related infections are the most important dose-limiting toxicities in anticancer chemotherapy and

148 Four patients had dose-limiting toxicities in cycle 1 (phase I).

149 125 mg daily, was determined on the basis of dose-limiting toxicities in four patients (100 mg, grade

150 cohorts of at least three patients based on dose-limiting toxicities in the first treatment cycle un

151 nib and capecitabine were escalated based on dose-limiting toxicities in the first treatment cycle un

152 Dose-limiting toxicities in two patients at 70 mg/m(2) w

153 Dose-limiting toxicity in DL2 was grade 3 proteinuria an

154 nd the dose level with prospectively defined dose-limiting toxicity in less than one third of patient

155 mplement activation and associated pain, the dose-limiting toxicity in neuroblastoma immunotherapy.

156 severity of rash (the previously determined dose-limiting toxicity in patients receiving EIAEDs) see

157 acy of PI3Kalpha inhibitors while mitigating dose-limiting toxicity in patients with head and neck sq

158 Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide

159 Dose-limiting toxicity in the phase 1 portion was neutro

160 Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acu

161 Cytokine release syndrome (CRS) was the only dose-limiting toxicity (in three [6%] of 53 patients) an

162 Dose-limiting toxicities included diarrhea and neutropen

163 Non-dose-limiting toxicities included elevated serum transam

164 Dose-limiting toxicities included grade 3 fatigue (200 m

165 Dose-limiting toxicities included grade 4 fever, and pul

166 Dose-limiting toxicities included grade 4 thrombocytopen

167 Grade 3 dose-limiting toxicities included headache, nausea/vomit

168 Dose-limiting toxicities included hematuria, increased g

169 Non-dose-limiting toxicities included left ventricular dysfu

170 Five dose-limiting toxicities, including fatigue (n = 2), thr

171 cation to FGF19-driven HCC may be limited by dose-limiting toxicities mediated by FGFR1-3 receptors.

172 2, palifermin = 4) experienced a total of 11 dose-limiting toxicities (most often skin, respiratory,

173 Dose-limiting toxicities (n = 1 for each) were grade 3 h

174 amended to include pegfilgrastim because of dose-limiting toxicity (neutropenia), and a second dose-

175 injections, with no serious adverse events, dose-limiting toxicities, nor evidence for anti-VRC01 an

176 enrolled and 12 were evaluable for toxicity Dose limiting toxicity observed included grade 3 hyperbi

177 Dose-limiting toxicities observed during dose escalation

178 Dose-limiting toxicities observed in patients receiving

179 y administration was well tolerated, with no dose-limiting toxicities observed.

180 Two dose-limiting toxicities occurred at the 17 Gy dose leve

181 No deaths related to toxicity or dose-limiting toxicities occurred during induction.

182 No dose-limiting toxicities occurred during the first 6 wee

183 Hematologic dose-limiting toxicities occurred in vitamin-supplemente

184 Dose-limiting toxicities occurred with 21-day tipifarnib

185 No dose-limiting toxicities occurred, and a maximum-tolerat

186 No dose-limiting toxicities occurred, and no new safety sig

187 No deaths, serious adverse events, or dose-limiting toxicities occurred.

188 Temozolomide was well tolerated and no dose-limiting toxicities occurred.

189 No dose-limiting toxicities occurred.

190 No infusional reactions or dose-limiting toxicities occurred.

191 All were treated with 5 mg because no dose-limiting toxicities occurred.

192 Two dose-limiting toxicities occurred: one grade 4 seizure o

193 rates of clinically significant pneumonitis, dose-limiting toxicity occurred and was dominated by lat

194 One dose-limiting toxicity occurred at 200 mg (the patient d

195 Dose-limiting toxicity occurred at dose level 1 with pro

196 Dose-limiting toxicity occurred at level 6 (30-mg/m(2) b

197 Only one dose-limiting toxicity occurred, at the 20 mg/kg dose, a

198 ation schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 desig

199 ition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.

200 ncluding febrile neutropenia represent major dose-limiting toxicities of cancer chemotherapy.

201 The maximum tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreve

202 edule modifications in patients experiencing dose-limiting toxicities of erlotinib or similarly targe

203 Stent occlusions led to dose-limiting toxicities of grade 3 liver enzyme and bil

204 ose was temsirolimus 15 mg/IFN 6 MU based on dose-limiting toxicities of stomatitis, fatigue, and nau

205 ral neuropathy are the most frequently cited dose-limiting toxicities of this class of chemotherapeut

206 to establish the maximum tolerated dose and dose-limiting toxicity of bevacizumab when administered

207 Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effe

208 Acute mucositis is a dose-limiting toxicity of concurrent chemoradiotherapy r

209 oses can improve activity while reducing the dose-limiting toxicity of conventional dosing schedules.

210 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obse

211 Dose-limiting toxicity of grade 4 neutropenia in two of

212 umulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly le

213 time can temporally segregate efficacy from dose-limiting toxicity of streptozocin, a chemotherapeut

214 /kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate

215 Transient grade 3 hypophosphatemia (dose-limiting toxicity, one patient) and grade 3 pruritu

216 in is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and acquired resis

217 There were no reported dose-limiting toxicities or evidence of cumulative toxic

218 MABp1 was well tolerated, with no dose-limiting toxicities or immunogenicity.

219 No dose-limiting toxicities or relevant safety events were

220 across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose.

221 sored at the time of analysis as a result of dose-limiting toxicity or other reasons.

222 iscontinuations because of drug-related AEs, dose-limiting toxicities, or antidrug antibodies were re

223 tumumab 15 mg/kg, only two of whom had three dose-limiting toxicities: palmar-plantar erythrodysesthe

224 herapy, where high doses are required, their dose limiting toxicities preclude success.

225 Dose limiting toxicities, prolonged grade 4 neutropenia

226 One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus).

227 Three dose-limiting toxicities (QTc changes) occurred: one at

228 , to deliver a potent immunosuppressant with dose-limiting toxicity, rapamycin (Rapa) also known as S

229 one was generally well tolerated with only 1 dose-limiting toxicity reported (grade 3 pneumonia at 20

230 Two patients in cohort 2 developed grade 3 dose-limiting toxicity (seizures, renal insufficiency).

231 In the mild LD group, dose-limiting toxicity, specifically nausea/vomiting and

232 Because of dose-limiting toxicities (T-cell recovery >30 days in 2

233 Primary outcomes were dose-limiting toxicities, the maximum tolerated dose of

234 x given everolimus on days 1-14) without any dose-limiting toxicities; therefore, everolimus 10 mg/da

235 Phase I studies have shown the dose-limiting toxicity to be stomatitis, which can be ab

236 We observed no dose-limiting toxicity, treatment-induced immunosuppress

237 The dose-limiting toxicity using this novel schedule was hyp

238 The maximum-tolerated dose was 680 mg/d, and dose-limiting toxicity was a reversible and asymptomatic

239 Dose-limiting toxicity was acute tumor lysis syndrome re

240 that ABDNAZ was not myelosuppressive and no dose-limiting toxicity was apparent following daily admi

241 Dose-limiting toxicity was grade 3 diarrhea, and the MTD

242 The dose-limiting toxicity was grade 3 or 4 neutropenia, whi

243 ximum-tolerated dose was 200 mg/day, and the dose-limiting toxicity was grade 3 QT prolongation.

244 ong-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy.

245 Dose-limiting toxicity was not encountered, and ipilimum

246 Dose-limiting toxicity was not observed.

247 (n = 1), were observed with schedule A; one dose-limiting toxicity was observed (elevated AST/ALT) w

248 No dose-limiting toxicity was observed and the maximum tole

249 No dose-limiting toxicity was observed at any dose.

250 s with heavily pretreated ovarian cancer; no dose-limiting toxicity was observed in 16 patients treat

251 grade 3 or 4 toxicity event was reported, no dose-limiting toxicity was observed in 47 trials (57%).

252 Notably, no dose-limiting toxicity was observed in a Phase I clinica

253 No dose-limiting toxicity was observed in phase I once ever

254 Dose-limiting toxicity was observed in two of seven pati

255 Dose-limiting toxicity was reached at the 20-mCi dose, w

256 No dose-limiting toxicity was recorded with durvalumab plus

257 One dose-limiting toxicity was reported (grade 3 hyponatremi

258 One dose-limiting toxicity was reported in the 1.0 mg/kg coh

259 No dose-limiting toxicity was reported, and only three pati

260 Dose-limiting toxicity was reversible neurotoxicity.

261 One occurrence of dose-limiting toxicity was seen at 30 mg/kg: respiratory

262 Dose-limiting toxicity was seen in one patient each at 5

263 In group B, dose-limiting toxicity was seen in six of 23 melanoma pa

264 as used to determine maximum tolerated dose; dose-limiting toxicities were assessed during cycle 1.

265 Dose-limiting toxicities were assessed during the first

266 tuzumab deruxtecan from 0.8 to 8.0 mg/kg and dose-limiting toxicities were assessed over a 21-day cyc

267 MABp1 was well tolerated, no dose-limiting toxicities were experienced in this study,

268 Dose-limiting toxicities were fatigue, nausea, vomiting,

269 Dose-limiting toxicities were grade 2 mood alteration (8

270 Dose-limiting toxicities were grade 3 nausea, vomiting,

271 Dose-limiting toxicities were grade 3 palmar plantar ery

272 Dose-limiting toxicities were hepatic and renal.

273 No CP-751,871-related dose-limiting toxicities were identified.

274 Dose-limiting toxicities were mucositis and hand-foot sy

275 Two dose-limiting toxicities were noted in patients with mye

276 No dose-limiting toxicities were noted in the dose-escalati

277 No grades 3 to 4 or dose-limiting toxicities were noted, and a maximum-toler

278 No dose-limiting toxicities were noted.

279 No dose-limiting toxicities were observed and ocular advers

280 No dose-limiting toxicities were observed during cycle 1 of

281 Dose-limiting toxicities were observed in three (11%) of

282 In part 1 (13 patients), no dose-limiting toxicities were observed, and 16 mg/kg was

283 dose until we were able to establish that no dose-limiting toxicities were observed.

284 No dose-limiting toxicities were observed.

285 No dose-limiting toxicities were observed.

286 HGS004 was well tolerated, and no dose-limiting toxicities were observed.

287 No dose-limiting toxicities were observed.

288 Dose-limiting toxicities were rectal ulceration and prot

289 Dose-limiting toxicities were reported in two of three p

290 Although no protocol-defined dose-limiting toxicities were reported, a high incidence

291 Results No dose-limiting toxicities were reported; nine of 38 repor

292 The dose-limiting toxicities were reversible severe blurred

293 Dose-limiting toxicities were sepsis and neutropenia.

294 Serious AEs, sepsis episodes, and dose-limiting toxicities were similar between treatment

295 Dose-limiting toxicities were somnolence (n = 1), confus

296 Dose-limiting toxicities were supraventricular tachyarrh

297 Prespecified criteria for dose-limiting toxicity were not met.

298 Human clinical trials indicated no dose-limiting toxicity when administered at doses up to

299 We observed two dose-limiting toxicities with ricolinostat 160 mg twice

300 Constipation was the dose-limiting toxicity with both routes.